Get notified of page updates
Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
Clinicaltrials.gov identifier:NCT04548752
Glossary on
off
About the Study
NOTE: This study is no longer recruiting patients.
This study is researching whether adding the drug Pembrolizumab (Keytruda) to the Olaparib (Lynparza) works better than alone in treating people with pancreatic cancer who also have an inherited or mutation.
This Study is Open To:
NOTE: This study is no longer recruiting patients.
This Study is NOT Open To:
NOTE: This study is no longer recruiting patients.
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
Clinicaltrials.gov identifier:NCT04548752